Literature DB >> 16293624

Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-D-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy.

Joseph Joyce1, James Cook, Donald Chabot, Robert Hepler, Wesley Shoop, Qiuwei Xu, Thomas Stambaugh, Miguel Aste-Amezaga, Su Wang, Lani Indrawati, Mark Bruner, Arthur Friedlander, Paul Keller, Michael Caulfield.   

Abstract

The capsular polypeptide of Bacillus anthracis is composed of a unique polyglutamic acid polymer in which D-glutamate monomers are joined by gamma-peptidyl bonds. The capsule is poorly immunogenic, and efforts at exploiting the polymer for vaccine development have focused on increasing its inherent immunogenicity through chemical coupling to immune-stimulating protein carriers. The usual strategy has employed carbodiimide-based condensing reagents for activation of free alpha-carboxyl groups, despite reports that this chemistry may lead to chain scission. We have purified the high molecular mass capsule to >95% homogeneity and have demonstrated that the polymer contains >99% poly-gamma-D-glutamic acid. The predominant structure of the polymer as assessed by circular dichroism and multiangle laser light scattering was unordered at near-neutral pH. We investigated the effects of various activation chemistries, and we demonstrated that carbodiimide treatment under aqueous conditions results in significant cleavage of the gamma-peptidyl bond, whereas scission is significantly reduced in nonaqueous polar solvents, although undesired side chain modification was still observed. An activation chemistry was developed using the triazine-based reagent 4-(4,6-dimethoxy (1,3,5)triazin-2-yl)-4-methylmorpholinium chloride, which allowed for controlled and reproducible derivatization of alpha-carbonyls. In a two-pot reaction scheme, activated capsule was derivatized with a sulfhydryl-reactive heterobifunctional moiety and was subsequently coupled to thiolated carrier protein. This conjugate elicited very high capsule-specific immune titers in mice. More importantly, mice immunized with conjugated capsule exhibited good protection against lethal challenge from a virulent B. anthracis strain in two models of infection. We also showed, for the first time, that treatment of capsule with carbodiimide significantly reduced recognition by capsule-specific antisera concurrent with the reagent-induced reduction of polymer mass. The data suggested that for vaccine development, maintenance of the high mass of the polymer may be important.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16293624     DOI: 10.1074/jbc.M509432200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule.

Authors:  Zhaochun Chen; Rachel Schneerson; Julie Lovchik; C Rick Lyons; Huaying Zhao; Zhongdong Dai; Joanna Kubler-Kielb; Stephen H Leppla; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

2.  Bacillus anthracis Capsular Conjugates Elicit Chimpanzee Polyclonal Antibodies That Protect Mice from Pulmonary Anthrax.

Authors:  Zhaochun Chen; Rachel Schneerson; Julie A Lovchik; Zhongdong Dai; Joanna Kubler-Kielb; Liane Agulto; Stephen H Leppla; Robert H Purcell
Journal:  Clin Vaccine Immunol       Date:  2015-06-03

3.  Sortase-conjugation generates a capsule vaccine that protects guinea pigs against Bacillus anthracis.

Authors:  Gabriella Garufi; Ya-Ting Wang; So-Young Oh; Hannah Maier; Dominique M Missiakas; Olaf Schneewind
Journal:  Vaccine       Date:  2012-03-23       Impact factor: 3.641

4.  Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule.

Authors:  Thomas R Kozel; Peter Thorkildson; Suzanne Brandt; William H Welch; Julie A Lovchik; David P AuCoin; Julpohng Vilai; C Rick Lyons
Journal:  Infect Immun       Date:  2006-10-23       Impact factor: 3.441

5.  Human Innate Immune Cells Respond Differentially to Poly-γ-Glutamic Acid Polymers from Bacillus anthracis and Nonpathogenic Bacillus Species.

Authors:  Tanya M Jelacic; Wilson J Ribot; Jennifer Chua; Anne E Boyer; Adrian R Woolfitt; John R Barr; Arthur M Friedlander
Journal:  J Immunol       Date:  2020-01-13       Impact factor: 5.422

6.  Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis.

Authors:  Angelo Scorpio; Donald J Chabot; William A Day; David K O'brien; Nicholas J Vietri; Yoshifumi Itoh; Mansour Mohamadzadeh; Arthur M Friedlander
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

7.  Treatment of experimental anthrax with recombinant capsule depolymerase.

Authors:  Angelo Scorpio; Steven A Tobery; Wilson J Ribot; Arthur M Friedlander
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

8.  Defensive strategies of Bacillus anthracis that promote a fatal disease.

Authors:  Jeremy Mogridge
Journal:  Drug Discov Today Dis Mech       Date:  2007

9.  Transcriptional profiling of murine organ genes in response to infection with Bacillus anthracis Ames spores.

Authors:  Scott T Moen; Linsey A Yeager; William S Lawrence; Cindy Ponce; Cristi L Galindo; Harold R Garner; Wallace B Baze; Giovanni Suarez; Johnny W Peterson; Ashok K Chopra
Journal:  Microb Pathog       Date:  2007-10-23       Impact factor: 3.738

10.  An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions.

Authors:  Joseph G Joyce; Isaac J Krauss; Hong C Song; David W Opalka; Karen M Grimm; Deborah D Nahas; Mark T Esser; Renee Hrin; Meizhen Feng; Vadim Y Dudkin; Michael Chastain; John W Shiver; Samuel J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.